ATPase H+ transporting V0 subunit c pseudogene 3Genealiases: []
Q-omics provides the consensus-scored ATP6V0CP3 profile across patient tissues and cancer cell-line models. ATP6V0CP3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP6V0CP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ATP6V0CP3 RNA expression shows 11,552 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRC, and PAAD as cancer lineages where ATP6V0CP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP6V0CP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP6V0CP3 survival associations across molecular data types. ATP6V0CP3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP6V0CP3 RNA expression–survival associations across cancer types. High ATP6V0CP3 expression shows unfavorable associations in SKCM and ACC, but favorable associations in KIRC, MESO, UCS and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP6V0CP3 RNA expression.
This table summarizes ATP6V0CP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP6V0CP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP6V0CP3 shows lower tumor expression in KIRC, KIRP, KICH, THCA, LUSC and BLCA. The KIRC box plot shows higher ATP6V0CP3 RNA expression in normal versus tumor tissue (log2 FC = −0.778, t-test p < 0.001).
This table shows molecular features associated with ATP6V0CP3 in patient tissues and cancer cell lines. In patient samples, ATP6V0CP3 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
